Yueh-Yun Chi
Research Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Year:
2026
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
Year:
2025
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry ( n = 251,632). Pearson’s χ 2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
Year:
2025
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
Year:
2025
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
Year:
2025
Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared with earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione (GSH) production. This study tested the optimal dose, safety, and efficacy of NAC to prevent CIHL. Patients and Methods: In this nonrandomized, controlled phase Ia/Ib trial, children and adolescents newly diagnosed with nonmetastatic, cisplatin-treated tumors received NAC intravenously 4 hours post-cisplatin. The trial performed dose-escalation across three dose levels to establish a safe dose that exceeded the targeted peak serum NAC concentration of 1.5 mmol/L (as identified from preclinical models). Patients with metastatic disease or who were otherwise ineligible were enrolled in an observation-only/control arm. To evaluate efficacy, serial age-appropriate audiology assessments were performed. Integrated biology examined genes involved in GSH metabolism and post-NAC GSH concentrations. Results: Of 52 patients enrolled, 24 received NAC and 28 were in the control arm. The maximum tolerated dose was not reached; analysis of peak NAC concentration identified 450 mg/kg as the recommended phase II dose (RP2D). Infusion-related reactions were common. No severe adverse events occurred. Compared with the control arm, NAC decreased likelihood of CIHL at the end of cisplatin therapy [OR, 0.13; 95% confidence interval (CI), 0.021–0.847; P = 0.033] and recommendations for hearing intervention at end of study (OR, 0.082; 95% CI, 0.011–0.60; P = 0.014). NAC increased GSH; GSTP1 influenced risk for CIHL and NAC otoprotection. Conclusions: NAC was safe at the RP2D, with strong evidence for efficacy to prevent CIHL, warranting further development as a next-generation otoprotectant.
Year:
2025
Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared to earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione production. This study tested the optimal dose, safety, and efficacy of NAC to prevent CIHL. Patients and Methods: In this nonrandomized, controlled Phase 1a/1b trial, children and adolescents newly diagnosed with non-metastatic, cisplatin-treated tumors received NAC intravenously four hours post-cisplatin. The trial performed dose-escalation across three dose levels to establish a safe dose that exceeded the targeted peak serum NAC concentration of 1.5 mM (as identified from preclinical models). Patients with metastatic disease or otherwise ineligible were enrolled in an observation-only/control arm. To evaluate efficacy, serial age-appropriate audiology assessments were performed. Integrated biology examined genes involved in glutathione metabolism and post-NAC glutathione concentrations. Results: Of 52 patients enrolled, 24 received NAC and 28 were in the control arm. The maximum tolerated dose was not reached; analysis of peak [NAC] identified 450 mg/kg as the recommended Phase 2 dose (RP2D). Infusion-related reactions were common. No severe adverse events occurred. Compared to the control arm, NAC decreased likelihood of CIHL at end of cisplatin therapy (odds ratio [OR] 0.13, 95% confidence interval [CI] 0.021-0.847, p=0.033) and recommendations for hearing intervention at end of study (OR 0.082, 95%CI 0.011-0.60, p=0.014). NAC increased glutathione; GSTP1 influenced risk for CIHL and NAC otoprotection. Conclusion: NAC was safe at the RP2D with strong evidence for efficacy to prevent CIHL, warranting further development as a next-generation otoprotectant. Trial number: NCT02094625
Year:
2024
Year:
2023
Collaborators (13)
Jorge Nieva
Professor of Clinical Medicine
University of Southern California
Etan Orgel
Professor of Clinical Pediatrics
University of Southern California
Andrew Doan
-
Leslie Muldoon
Associate Professor
Oregon Health & Science University
Michael N. Neely
Professor of Pediatrics
University of Southern California
Reuven Schore
George Washington University
Colin Ross
Professor
The University of British Columbia
David R. Freyer
-
Edward A Neuwelt
Oregon Health & Science University
Laurie Eisenberg
University of Southern California
Michael Roth
Associate Professor of Pediatrics
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Caryn Lerman
University of Southern California
Britni R. Belcher
University of Southern California
Make your next move.
Prepare your application
Review drafts before you send them.